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Introduction
Chronic urticaria (CU) is defined as the occurrence 
of daily, or almost daily, wheals and itching for at least 
6 weeks. It is a common and potentially debilitating skin 
condition that affects up to 1% of the general population 
with variable duration, typically several months, but oc-
casionally decades [1]. Chronic idiopathic urticaria (CIU), 
defined as the occurrence of CU, with no obvious cause, 
constituting up to 70% of cases [2, 3].
Both children and adults can develop CU, although 
it is more common in adults. Women are affected twice 
as often as men, and the condition typically begins in 
the third to fifth decade of life [4, 5]. Although not the 
sole cause of symptoms, certain factors aggravate CU in 
a substantial subset of patients. These include physical 
factors, nonsteroidal anti-inflammatory drugs (NSAIDs), 
alcohol, stress, and food allergy. 
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Abst rac t
Introduction: Chronic urticaria (CU) is defined as the presence of urticaria on most days of the week for a period 
of 6 weeks or longer. Some studies have reported an association between CU and Helicobacter pylori (H. pylori) 
infection.
Aim: To determine the prevalence of H. pylori infection using the stool antigen test in patients with idiopathic CU 
and to investigate the infected patients with CU following eradication of H. pylori.
Material and methods: One hundred patients with idiopathic CU and 100 healthy controls were referred to our 
clinic between May 2012 and June 2013 and were tested for H. pylori antigen. The patients infected with H. pylori 
received quadruple therapy for 2 weeks. To assess eradication efficacy, a repeated H. pylori stool antigen test was 
performed in each patient 6 weeks after the end of anti-H. pylori therapy. The effectiveness of eradication therapy 
on CU was assessed 3 months after treatment.
Results: Thirty-six percent patients with idiopathic CU were infected with H. pylori while 23% of the controls were 
infected. Response to eradication therapy was evident in 33 (91.67%) patients in whom H. pylori was eradicated 
while 3 (8.33%) patients showed no response despite eradication of H. pylori. Clinical follow-up of 33 successfully 
treated patients 3 months later revealed complete remission of urticaria in 54.5%, partial remission in 18.2%, and 
no improvement in 27.3%.
Conclusions: The results of our study suggest that H. pylori infection should be included in diagnostic workup of 
patients with no response to habitual treatment for CU or symptomatic gastrointestinal patients. For the diagnosis 
of H. pylori infection, one should consider the costs and accessibility of the population to the HpSA® stool antigen 
test and Urea breath test (UBT).
Key words: chronic urticaria, Helicobacter pylori, eradication.
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Chronic urticaria is associated with various autoim-
mune disorders [4]. There is a possible association with 
malignancies, although data are conflicting [6]. None of 
the theories of pathogenesis of CU has been fully estab-
lished [7]. The best-developed hypotheses include the au-
toimmune theory, theories involving histamine-releasing 
factors, and the cellular defects theory. Attempts have 
been made to associate some common chronic infec-
tions with CU, including Helicobacter pylori [8, 9], hepati-
tis A [10], and hepatitis C [11].
Chronic H. pylori gastritis affects two-thirds of the 
world’s population and is one of the most common 
chronic inflammatory disorders of humans. The ma-
jor clinical associations with chronic H. pylori gastritis 
are peptic ulcer disease and, less commonly, gastric 
cancer and lymphoma. Recent evidence suggests that 
H. pylori infections play a role in the pathogenesis of a va-
riety of skin diseases [12]. It is known that CU occasionally 
develops with H. pylori infection, but the association be-
tween urticaria and H. pylori remains unknown [13].
Aim
The aim of this study is to determine the prevalence 
of H. pylori infection using the stool antigen test in pa-
tients with CU and to investigate the infected patients of 
CU following eradication of H. pylori.
Material and methods
Patients and controls 
This study was approved by the Ethics Committee of 
the Ardabil University of Medical Sciences. This was a pro-
spective cross-sectional study. Patients presenting with CU 
to the dermatology out-patient clinic of Imam Khomeini 
Hospital in Ardabil, Iran, between May 2012 and June 2013 
were recruited for the study. A total of 100 patients with 
idiopathic CU and 100 healthy controls were included. The 
two groups were matched for age and sex. Physical exam-
ination and laboratory tests (complete blood cell count, 
renal and liver function, fasting blood glucose, serum cre-
atinine, erythrocyte sedimentation rate, antinuclear anti-
body, complement assays, and thyroid function test) were 
carried out at baseline and were normal to exclude other 
etiologies than H. pylori. Patients who met the following 
criteria were enrolled into this study: (1) urticaria duration 
of at least 6 weeks; (2) no cause of urticaria found despite 
extensive laboratory tests; (3) existence of gastrointesti-
nal symptoms in the medical history; and (4) consent to 
participate in the study. Criteria for exclusion included: 
(1) use of antibiotics, bismuth, or proton-pump inhibitors 
within the prior 4 weeks; (2) patients with previous gastric 
surgery; and (3) the coexistence of serious concomitant 
illness (e.g. decompensated liver cirrhosis or uremia). 
The H. pylori stool antigen test was performed in 
all study subjects. Prior to sampling, the questionnaire, 
including medical history and demographic data, was 
completed for each patient. All studied patients signed 
an informed consent form and declared their willingness 
to allow the application of their anonymous data for re-
search purposes. Table 1 shows the characteristics of the 
CU group and control group.
The patients infected with H. pylori received qua-
druple therapy with omeprazole (20 mg twice daily), 
amoxicillin (1 g twice daily), bismuth subcitrate (240 mg 
twice daily), and clarithromycin (500 mg twice daily) for 
2 weeks. All patients were followed up during the study 
duration of 3 months. To assess eradication efficacy, a re-
peated H. pylori stool antigen test was performed in each 
patient 6 weeks after the end of anti-H. pylori therapy. 
The effectiveness of eradication therapy on CU was as-
sessed 3 months after treatment, using a three-point rat-
ing scale, that is, complete remission, partial remission 
(50% or more), or no improvement.
Helicobacter pylori stool antigen test
A fresh stool sample was collected from each patient 
and stored at –20°C until analyzed. The H. pylori stool 
antigen test (GA GENERIC ASSAYS GmbH, Germany) was 
performed according to the manufacturer’s recommen-
dation. According to the manufacturer’s instructions 
(spectrophotometer, Avernest, stat fax 3200, USA), the 
cut-off value was obtained by the mean OD of negative 
control at 450 nm, plus 0.1. OD ≤ cut-off was defined neg-
ative, OD > cut-off was considered positive.
Table 1. Characteristics of chronic urticaria (CU) group and control group
Characteristics Patients with CU (N = 100) Controls (N = 100)  Value of p
Age [year] 37.64 ±16.04 37.55 ±16.26 0.943
Gender (male/female) 58/42 58/42 1.000
Place of residence (rural/city) 44/56 39/61 0.840
Education duration [year] 6.8 ±1.2 7.1 ±0.3 0.950
BMI [kg/m2] 70.2 ±12.2 69.7 ±11.3 0.850
CU disease duration [month] 15.34 ±10.73 –  –
BMI – body mass index.
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Statistical analysis
Diagnostic methods were compared by c2 and 
Student t-test statistical analysis, and p value of 
< 0.05 was considered statistically significant. The statis-
tical analysis was performed using analysis of variance 
and SPSS software (Version 19, SPSS Inc, United States).
Results
Two hundred patients were enrolled in the study 
(100 cases and 100 controls). In both groups, 58% were 
male and 42% were female. The mean age in the patients 
group was 37.64 ±16.04 years and in the control group 
it was 37.55 ±16.26 years. Other findings in the patients 
group were asthma (12.8%), allergic rhinitis (14.3%), and 
angioedema (47.8%). Based on the clinical characteristics 
of CU patients, the duration of the last CU episode was 
relatively long, between 5 months and 6 years (median 
15.34 months). All patients had received medications be-
fore coming to our clinic and most of them (94.13%) had 
combination therapy.
Thirty-six percent patients with CU were infected 
with H. pylori while 23% of the controls were infected. 
There was statistically a significant difference (p = 0.044) 
between the prevalence of H. pylori in patients with CU 
and controls. The infected patients with CU achieved 
quadruple therapy with omeprazole, amoxicillin, bismuth 
subcitrate, and clarithromycin for 14 days. Response to 
eradication of H. pylori was evident in 33 (91.67%) pa-
tients in whom H. pylori was eradicated while 3 (8.33%) 
patients showed no response despite eradication of 
H. pylori. Clinical follow-up of 33 successfully treated pa-
tients 3 months later revealed complete remission of ur-
ticaria in 54.5% (18/33), partial remission in 18.2% (6/33), 
and no improvement in 27.3% (9/33). In other words, 
72.7% (24/33) successfully treated patients showed 
remission of urticaria, while 27.3% (9/33) successfully 
treated patients showed no response. 
Discussion
Helicobacter pylori is a bacterium that is found in the 
stomach and is responsible for most cases of peptic ul-
cer and is one of the most common bacterial infections 
in humans [14]. There are several tests available to de-
tect the presence of H. pylori in the stomach. Among 
non-invasive diagnostic tests, H. pylori stool antigen test 
(HpSAT) and urea breath test (UBT) have higher accura-
cy than serological or urinary antibody-based tests. The 
American Gastroenterological Association recommends 
both HpSAT and UBT for the diagnosis of H. pylori infec-
tion in patients with dyspepsia [15]. The HpSAT has high 
sensitivity and specificity and is used for diagnosis as 
well as monitoring after treatment [16].
The importance of biofilm in the pathogenesis of 
H. pylori infection is not fully understood. Many research-
ers suggest that it may be responsible for the failure 
of H. pylori eradication and contribute to the survival of 
microorganisms in the focal infection, leading to reinfec-
tion [17]. Although Sonic hedgehog (Shh) signaling path-
way plays a principal role in gastric carcinogenesis, its role 
in H. pylori-associated gastritis is unclear. The results of 
some studies support the hypothesis of the involvement of 
Shh signaling pathway in H. pylori-associated gastritis [18].
Helicobacter pylori has been implicated in a variety 
of diseases that are not related to the gastrointestinal 
tract. The skin is an example and several studies have 
suggested an association with the following conditions 
[19, 20]: CU, rosacea, psoriasis, Sjögren syndrome, He-
noch-Schönlein purpura, alopecia areata, Sweet disease, 
systemic sclerosis, atopic dermatitis, Behçet’s disease, 
generalized pruritus (itch), nodular prurigo, immune 
thrombocytopenic purpura, lichen planus, and aphthous 
ulceration. A possible role for H. pylori in the pathogen-
esis of gastroesophageal reflux disease (GERD) has also 
been suggested in a growing number of studies. The as-
sociation between H. pylori infection and functional dys-
pepsia (FD) is unclear. Whether patients with FD should 
receive H. pylori eradication therapy remains controver-
sial [21].
Several studies have found a link between H. py-
lori infection and CU. It is thought that infection with 
H. pylori increases the permeability of the stomach lin-
ing and thus increases the exposure to allergens (sub-
stances that causes an allergy) in the gastro-intestinal 
tract. Also, the immune response to H. pylori produces 
antibodies that may encourage release of histamine in 
the skin [22]. IgE-containing cells in gastric and duodenal 
mucosa seem to be the culprits, although there is limited 
evidence for HP-specific IgE. Thus, the possibility that pa-
tients with urticaria develop specific IgE against H. pylori 
is an attractive pathogenic explanation that unfortunate-
ly has not been confirmed yet [19]. 
The immunomodulatory role of H. pylori infection in 
CU is a subject of intensive debate. This immunomodu-
lation is not only dependent on the virulence of H. pylori 
but also on host and environmental factors. An alter-
native possibility is that immunological stimulation by 
chronic infection may produce, through mediator release, 
a non-specific increase in sensitivity of the cutaneous 
vasculature to agents that enhance vascular permeabil-
ity [19]. Furthermore, IgG and IgA antibodies to 19-kDa 
H. pylori-associated lipoprotein were found to play a role 
in the pathogenesis of CU [23].
A number of studies in several countries showed the 
high prevalence of H. pylori infection in CU patients, fol-
lowed by clinical remission of CU after H. pylori eradi-
cation therapy. In the first one of these studies, back in 
1994, Kolibasova et al. [24] assessed 21 patients with 
chronic urticaria and H. pylori infection. Eradication ther-
apy against the bacterium led to remission of urticaria in 
95% of the cases. Later on, Bohmeyer et al. [25] in 1996, 
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carried out endoscopic assessment in 10 patients with 
CU, finding H. pylori in the gastric mucosa in 8 of them; 
they reported that the skin lesions disappeared within 
a few days of treatment with amoxicillin and omeprazole. 
Table 2 shows a possible association between CU and 
H. pylori infection in the literature.
In the present study, we found that the prevalence 
rate of H. pylori infection is 36% in our CU patients. Twen-
ty-four (72.7%) successfully treated patients showed re-
mission of urticaria, while 9 (27.3%) successfully treated 
patients showed no response. Wustlich et al. [26] studied 
30 patients with CU and H. pylori infection, who were giv-
en eradication therapy with amoxicillin and omeprazole; 
the success or otherwise of the eradication therapy was 
assessed using a breath test (the eradication ratio was 
80%). After 6 months’ follow-up they observed improve-
ment or remission of the urticaria in 8 patients (26.7%). 
However, this study had no control group, and the results 
are compared to a published 6% spontaneous remission 
rate of urticaria. The results of this study did not support 
the preliminary data of previous studies.
Conflicting reports have been published. Some sug-
gest that H. pylori eradication in patients with CU leads 
to an improvement in the symptoms of CU, while oth-
ers showed no improvement (Table 2). Hellmig et al. [27] 
concluded that there is no evidence that eradication of 
H. pylori improves the outcome in patients with CU. The 
high rate of spontaneous remission and the coexistence 
of multiple foci will always obscure the evaluation of any 
specific antimicrobial therapy. 
In 2012, Kołacińska-Flont et al. [28] have compared 
the anti-H. pylori IgG titer in 62 patients with CIU and 
55 control subjects and evaluated the effect of H. pylori 
eradication on urticaria. They concluded that the anti- 
H. pylori IgG titer was similar in patients with CIU and 
controls. Helicobacter pylori eradication had no effect on 
urticaria in anti-H. pylori IgG positive CIU patients with 
gastric complaints. In 2014, Yoshimasu et al. [13] studied 
the effect of eradication therapy for urticaria with high 
titers of anti-H. pylori IgG antibody. They concluded that, 
regardless of it being acute or chronic urticaria, the high 
titer of anti-H. pylori, IgG antibody can be an indicator 
for undergoing upper endoscopy, and eradication thera-
py would be strongly recommended.
In CU there is a lot of evidence for different infec-
tions, but randomized controlled trials are missing. The 
prevalence of infections is not increased but in suscep-
tible patients the immune response may lead to the de-
velopment of CU. Interestingly, there is evidence for an 
infection-associated auto reactive response at least in 
the subgroup with a positive autologous serum skin test. 
A variety of mechanisms have been invoked to explain 
these observations, including molecular mimicry. Some 
bacterial infections such as Streptococcus, Mycoplasma 
pneumoniae, Borrelia can be also found in association 
with CU [10]. The therapeutic response observed follow-
ing the administration of amoxicillin and clarithromycin 
(two broad-spectrum antibiotics) may also be due to the 
eradication of other bacteria related to CU. In order to 
improve the healing effectiveness and to decrease the 
risk of adverse effects, not only appropriate drug selec-
tion but also optimal dosage and duration of treatment 
are essential [29].
Table 2. Association between chronic urticaria (CU) and H. pylori infection in the literature
Reference Country Year Total number  
of patients with CU




Bohmeyer et al. [25] Germany 1996 10 8 (80) 8/8 (100)
Tebbe et al. [34] Germany 1996 25 17 (68) 14/17 (82.3)
Valsecchi et al. [45] Italy 1998 125 31 (62) 3/29 (10)
Di Campli et al. [9] Italy 1998 42 18 (42.8) 13/16 (81.2)
Ozkaya-Bayazit et al. [35] Turkey 1998 35 23 (65.7) 5/17 (29.4)
Bonamigo et al. [36] Brazil 1999 18 18 (100) 10/12 (83.3)
Daudén et al. [37] Spain 2000 25 15 (60) 8/14 (57)
Erel et al. [44] Turkey 2000 38 29 (76) 1/25 (4)
Sakurane et al. [38] Japan 2002 50 Not stated Not stated
Fukuda et al. [39] Japan 2004 50 19 (38) 17/17 (100)
Magen et al. [40] Israel 2007 78 45 (57.7) Not stated
Yadav et al. [41] India 2008 68 48 (70.58) 39/48 (81.2)
Akashi et al. [42] Japan 2011 82 25 (30.5) Not stated
Chiu et al. [43] Taiwan 2013 14 11 (78.6) 8/11 (72.7)
This study Iran 2014 100 36 (36) 24/33 (72.7)
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As recent studies have demonstrated, IgG autoan-
tibodies against IgE and/or FcεRIα can be found in the 
sera of one-third of patients with idiopathic CU, and it 
is postulated that infection with H. pylori may induce 
production of pathogenic antibodies possibly by molec-
ular mimicry [30]. A growing body of evidence suggests 
that 30–50% of CU results from an autoimmune process 
involving functional histamine-releasing anti-FcεRIα au-
toantibodies or less commonly, anti-IgE-autoantibodies 
[31]. Once this occurs, the production of antibodies might 
continue even after the eradication of H. pylori infection, 
explaining the lack of clinical improvement after eradica-
tion seen in some studies [19].
To summarize, clinical trials including large numbers 
of patients are needed to establish a possible relation-
ship between gastrointestinal findings and CU. To cure 
at least some patients from quality-of-life reducing CU, 
it seems worthwhile to eradicate H. pylori in all patients 
with CU and H. pylori infection. A positive effect is pro-
posed for the eradication of H. pylori [19, 32, 33].
Conclusions
Helicobacter pylori may have a role in some patients 
with idiopathic CU. The results of our study suggest that 
H. pylori infection should be included in diagnostic work-
up of patients with no response to habitual treatment 
for CU or symptomatic gastrointestinal patients. For the 
diagnosis of H. pylori infection one should consider the 
costs and accessibility of the population to the HpSA® 
stool antigen test and urea breath test (UBT).
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